Fyb (Fyn-binding protein) inhibitors are a class of chemical compounds that specifically target and inhibit the Fyb protein, which is involved in signaling pathways that regulate cellular processes such as cytoskeletal organization, cell adhesion, and motility. Fyb interacts with the Src-family tyrosine kinase Fyn, playing a key role in transmitting signals from surface receptors to intracellular signaling cascades. Fyb is also associated with actin dynamics and is important for the formation of cell junctions and immune cell functions. Inhibitors of Fyb disrupt its interaction with Fyn or other associated proteins, thereby altering signal transduction pathways that influence cell structure and movement. These inhibitors are useful for understanding how Fyb regulates cellular architecture and its role in coordinating signaling events during dynamic cellular responses.
Chemically, Fyb inhibitors are often small molecules or peptides designed to interfere with specific domains of the Fyb protein, particularly the regions involved in protein-protein interactions. Some inhibitors may bind directly to the Fyn-binding site on Fyb, blocking its ability to associate with kinases or other downstream effectors. Others may work by altering the conformation of Fyb, preventing it from interacting with cytoskeletal components or signaling proteins. By inhibiting Fyb, researchers can explore how this protein contributes to cytoskeletal rearrangement, cell motility, and adhesion. Additionally, Fyb inhibitors help to elucidate the role of this protein in signal transduction, offering insights into the molecular mechanisms that govern cell communication and structural integrity, particularly in immune and epithelial cells. Through the use of Fyb inhibitors, scientists can gain a deeper understanding of how intracellular signaling and cytoskeletal dynamics are coordinated to maintain cellular functions.
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
An immunosuppressant, Cyclosporine A inhibits calcineurin, thereby affecting T-cell activation in which FYB may play a role. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $76.00 $148.00 | 9 | |
Another calcineurin inhibitor, FK506 impacts TCR signaling and T-cell activation, potentially influencing FYB-associated pathways. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
A calcium ionophore, Ionomycin, in combination with PMA, is commonly used to activate T-cells, potentially affecting FYB-mediated processes. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
An inhibitor of Src family kinases, PP2 can affect TCR signaling, potentially impacting FYB's role in this pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A broad-spectrum tyrosine kinase inhibitor, Dasatinib can influence TCR signaling and T-cell activation, potentially affecting FYB. | ||||||
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $127.00 $192.00 $269.00 $502.00 $717.00 $1380.00 $2050.00 | 114 | |
A STAT3 inhibitor, Stattic can modulate cytokine signaling and T-cell responses, potentially impacting FYB activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor, LY294002 can affect various cellular processes, including TCR signaling, potentially impacting FYB. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor, Wortmannin may influence TCR signaling and T-cell activation, potentially affecting FYB. |